Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
Research frequently cites 0.5% as an effective sweet spot, balancing meaningful results against low irritation risk
If you move from 0.5% to 1% to 2% in quick succession, you can't know which concentration was responsible for any observed improvements
Impact of Toxins on P450 Enzymes and Methylation Exposure to toxins, drugs, and alcohol can impair the activity of P450 enzymes, leading to a decrease in SAMe production and impaired methylation
Combining with other peptides The glow stack can be combined with other peptides for enhanced effects
